Neurological & Mental Health: Depression, Anxiety, ADHD & Alzheimer's Through a Neuroinflammatory Lens

Introduction

Mental and neurological health conditions are among the most prevalent and debilitating of our time. Depression affects over 280 million people globally; anxiety disorders affect 300 million; ADHD is diagnosed in approximately 10% of children and a growing proportion of adults; and Alzheimer's disease — the most common form of dementia — affects over 55 million people worldwide, with projections suggesting this number will triple by 2050.

Conventional psychiatry and neurology have largely approached these conditions through a neurotransmitter deficit model — depression as a serotonin deficiency, ADHD as a dopamine dysregulation, Alzheimer's as an amyloid accumulation problem. Yet decades of research and billions of dollars invested in this framework have produced only modest therapeutic advances, with high rates of treatment resistance and significant side effect burdens.

A paradigm shift is underway. A growing body of evidence — supported by researchers including Cairns, Andries, Noori, Seyyedabadi, Makis, and Seyfried et al. — points to neuroinflammation as a central, unifying driver of depression, anxiety, ADHD, and neurodegeneration. This framework not only explains why conventional treatments so often fall short, but opens the door to powerful integrative strategies that address root causes rather than masking symptoms.

Part I: The Neuroinflammatory Framework

What Is Neuroinflammation?

Neuroinflammation refers to inflammatory processes occurring within the central nervous system (CNS), primarily driven by activated microglia — the brain's resident immune cells — and reactive astrocytes. Under normal conditions, microglia perform essential maintenance functions: clearing cellular debris, pruning synapses, and monitoring for pathogens. When chronically activated, however, microglia release pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-18), reactive oxygen species (ROS), and glutamate, creating a toxic neuroinflammatory environment that impairs neuronal function, disrupts neurotransmitter synthesis, damages myelin, and ultimately drives neurodegeneration.

Key drivers of chronic neuroinflammation include:

• Systemic inflammation — peripheral inflammatory cytokines cross the blood-brain barrier (BBB) and activate central microglia
• Gut dysbiosis and leaky gut — LPS and other microbial products translocate into the bloodstream and reach the brain via the gut-brain axis (see our Gut Microbiome guide)
• Mitochondrial dysfunction — impaired neuronal energy metabolism generating excess ROS (Seyfried et al.)
• BBB disruption — allowing peripheral immune cells and inflammatory mediators to infiltrate the CNS
• Chronic stress — HPA axis dysregulation elevating cortisol, which activates microglia and suppresses neurogenesis
• Infections and post-infectious immune activation — viral and bacterial infections triggering persistent microglial activation
• ECS dysregulation — reduced endocannabinoid tone impairing the brain's endogenous anti-inflammatory system (see our ECS guide)

The Kynurenine Pathway

A critical mechanistic link between inflammation and mental health is the kynurenine pathway. When inflammatory cytokines (particularly IFN-γ and TNF-α) activate the enzyme IDO1 (indoleamine 2,3-dioxygenase), tryptophan — the precursor to serotonin — is diverted away from serotonin synthesis and toward the kynurenine pathway, producing neuroactive metabolites including quinolinic acid (a potent NMDA receptor agonist and neurotoxin) and kynurenic acid. This explains why inflammation causes depression independently of serotonin deficiency — and why SSRIs, which target serotonin reuptake, are ineffective in inflammation-driven depression.

Part II: Depression Through a Neuroinflammatory Lens

The inflammatory theory of depression is now one of the most robust frameworks in psychiatry. Key evidence includes:

• Elevated inflammatory markers (CRP, IL-6, TNF-α, IL-1β) in depressed patients, particularly those with treatment-resistant depression
• Administration of inflammatory cytokines (e.g., IFN-α for hepatitis C treatment) reliably induces depression in previously healthy individuals
• Anti-inflammatory interventions (NSAIDs, omega-3s, curcumin) demonstrate antidepressant effects in clinical trials
• Microglial activation visible on PET imaging in depressed patients
• Strong association between depression and inflammatory conditions including autoimmune disease, metabolic syndrome, and gut dysbiosis

Neuroinflammation drives depression through multiple mechanisms: kynurenine pathway activation reducing serotonin availability; glutamate excitotoxicity impairing synaptic plasticity; suppression of BDNF (brain-derived neurotrophic factor) impairing neurogenesis; HPA axis dysregulation elevating cortisol; and disruption of the reward circuitry via inflammatory effects on dopamine signaling.

Andries et al. have highlighted the gut-brain axis as a critical bidirectional pathway in depression — gut dysbiosis drives neuroinflammation via LPS translocation and kynurenine pathway activation, while depression itself worsens gut dysbiosis via stress-induced gut barrier disruption.

Part III: Anxiety Through a Neuroinflammatory Lens

Anxiety disorders — including generalized anxiety disorder (GAD), panic disorder, social anxiety, and PTSD — share neuroinflammatory features with depression:

• Elevated IL-6, TNF-α, and CRP in anxiety disorder patients
• Microglial activation in the amygdala and prefrontal cortex — brain regions central to fear processing and emotional regulation
• HPA axis hyperactivation driving cortisol-mediated neuroinflammation
• Reduced anandamide levels — ECS deficiency impairing fear extinction and stress resilience
• Gut dysbiosis disrupting GABA and serotonin production via the gut-brain axis

The amygdala — the brain's fear center — is particularly sensitive to inflammatory signals. Microglial activation in the amygdala amplifies fear responses and impairs the prefrontal cortex's ability to regulate emotional reactivity, creating the hypervigilance and catastrophizing characteristic of anxiety disorders.

Noori et al. have reviewed the evidence for natural anti-inflammatory compounds in anxiety, noting that agents targeting microglial activation and the kynurenine pathway offer superior outcomes in inflammation-driven anxiety compared to conventional anxiolytics.

Part IV: ADHD Through a Neuroinflammatory Lens

ADHD — characterized by inattention, hyperactivity, and impulsivity — has traditionally been framed as a dopamine and norepinephrine dysregulation disorder. Emerging evidence points to neuroinflammation as a significant contributing factor:

• Elevated inflammatory markers (IL-6, TNF-α, CRP) in children and adults with ADHD
• Higher rates of ADHD in children with autoimmune conditions, allergies, and gut dysbiosis
• Microglial activation impairing prefrontal cortex dopaminergic signaling — the neural substrate of executive function and attention
• Mitochondrial dysfunction in neuronal energy metabolism impairing sustained attention and cognitive control
• Gut-brain axis dysregulation — gut dysbiosis is strongly associated with ADHD; probiotic interventions show promise in reducing ADHD symptoms
• Omega-3 deficiency — EPA and DHA are essential for neuronal membrane integrity and anti-inflammatory signaling; deficiency is consistently found in ADHD and supplementation demonstrates clinical benefit

Seyfried et al.'s mitochondrial framework is particularly relevant to ADHD — the prefrontal cortex is among the most metabolically demanding brain regions, and mitochondrial dysfunction disproportionately impairs its function, producing the executive function deficits characteristic of ADHD.

Part V: Alzheimer's Disease & Dementia Through a Neuroinflammatory Lens

Alzheimer's disease (AD) is the most common neurodegenerative disease and the sixth leading cause of death in the US. The dominant amyloid hypothesis — that amyloid-β plaques cause AD — has driven drug development for decades, yet virtually every amyloid-targeting drug has failed in clinical trials, raising fundamental questions about the primacy of amyloid in AD pathogenesis.

An alternative neuroinflammatory and metabolic framework is gaining traction:

• Neuroinflammation as a primary driver — chronic microglial activation precedes amyloid deposition in many cases; amyloid may be a downstream consequence of neuroinflammation rather than its cause
• Mitochondrial dysfunction — Seyfried et al. have argued that impaired neuronal energy metabolism is upstream of both amyloid accumulation and tau pathology; the brain's inability to efficiently use glucose ("type 3 diabetes" hypothesis) drives AD progression
• Insulin resistance in the brain — reduced insulin signaling in neurons impairs synaptic plasticity, promotes tau hyperphosphorylation, and accelerates neurodegeneration
• Gut-brain axis — gut dysbiosis drives neuroinflammation via LPS translocation; specific microbial signatures are associated with AD risk and progression
• ApoE4 genotype — the strongest genetic risk factor for AD; ApoE4 impairs lipid metabolism, mitochondrial function, and neuroinflammation resolution
• Herpes simplex virus (HSV-1) — emerging evidence implicates HSV-1 reactivation in the brain as a trigger for amyloid deposition and neuroinflammation in genetically susceptible individuals

Seyyedabadi et al. have highlighted the IL-6/STAT3 axis as a key driver of neuroinflammation in AD, with STAT3 activation in microglia promoting a chronic pro-inflammatory state that accelerates neurodegeneration.

Part VI: Integrative Approaches

Low Dose Naltrexone (LDN)

LDN's TLR4 antagonism and microglial suppression make it one of the most directly relevant agents for neuroinflammatory mental health conditions. By reducing TNF-α, IL-1β, and IL-6 in the CNS, LDN addresses the inflammatory drivers of depression, anxiety, and neurodegeneration. Cairns et al. have documented LDN's efficacy in reducing neuroinflammatory burden and improving mood, cognition, and quality of life across multiple neurological conditions. Clinical observations support LDN's use in treatment-resistant depression, anxiety, and early neurodegeneration.

Ivermectin

Ivermectin's NF-κB inhibition and NLRP3 inflammasome suppression reduce neuroinflammatory cytokine production. Its antiviral properties are particularly relevant given the emerging evidence for viral triggers (HSV-1, EBV) in neurodegeneration and treatment-resistant depression. Makis et al. have highlighted ivermectin's neuroprotective potential via its anti-inflammatory and antiviral mechanisms.

Niclosamide

Niclosamide's STAT3 inhibition directly targets the IL-6/STAT3 neuroinflammatory axis implicated in AD and depression. Its mTOR inhibition promotes neuronal autophagy — clearing damaged proteins including amyloid-β and tau — and its mitochondrial uncoupling effects may support neuronal energy metabolism. Seyyedabadi et al. have highlighted STAT3 as a high-value target in neuroinflammatory disease.

DMSO

DMSO's free radical scavenging and BBB-penetrating properties make it a valuable neuroprotective adjunct. Its ability to carry co-administered compounds across the BBB is particularly relevant for delivering anti-inflammatory agents directly to CNS tissue. Cairns et al. have noted DMSO's historical use in neurological conditions and its underexplored neuroprotective potential.

CBD & THC

The endocannabinoid system is deeply involved in neurological and mental health regulation. CBD's mechanisms relevant to neurological and mental health include:

• 5-HT1A activation — anxiolytic and antidepressant effects comparable to buspirone
• FAAH inhibition — increasing anandamide, improving stress resilience and fear extinction
• Microglial CB2 activation — reducing neuroinflammation in depression, anxiety, and neurodegeneration
• BDNF upregulation — promoting neurogenesis in the hippocampus (impaired in depression and AD)
• Neuroprotection — reducing glutamate excitotoxicity and oxidative stress in neurodegeneration

THC at low doses demonstrates anxiolytic, antidepressant, and neuroprotective effects via CB1 activation. High doses can worsen anxiety — careful titration is essential. CBD:THC combinations (high CBD ratio) are preferred for anxiety and depression; balanced 1:1 ratios may be appropriate for neurodegeneration and severe treatment-resistant conditions under medical supervision.

Botanical & Nutritional Agents

• Curcumin — crosses the BBB, reduces microglial activation, inhibits amyloid aggregation, upregulates BDNF; clinical evidence in depression and early AD
• Lion's Mane Mushroom — stimulates NGF synthesis promoting neurogenesis and remyelination; clinical evidence in mild cognitive impairment and depression
• Omega-3 (EPA/DHA) — essential for neuronal membrane integrity and anti-neuroinflammatory signaling; strong evidence in depression, ADHD, and cognitive decline
• Magnesium L-threonate — the only form of magnesium shown to cross the BBB; improves synaptic density and cognitive function; reduces anxiety via NMDA receptor modulation
• Ashwagandha — reduces cortisol, suppresses HPA axis hyperactivation, and demonstrates anxiolytic and antidepressant effects in clinical trials
• Saffron (Crocus sativus) — demonstrated antidepressant efficacy comparable to SSRIs in multiple RCTs; mechanisms include serotonin reuptake inhibition and anti-neuroinflammatory effects
• Bacopa monnieri — adaptogenic herb with clinical evidence for improving memory, attention, and processing speed; reduces neuroinflammation and oxidative stress
• Phosphatidylserine — essential phospholipid for neuronal membrane integrity; clinical evidence in age-related cognitive decline and ADHD
• NAD+ precursors (NMN/NR) — support mitochondrial function in neurons; directly relevant to Seyfried et al.'s metabolic framework for neurodegeneration

Metabolic & Lifestyle Interventions

• Ketogenic diet — provides ketone bodies as alternative neuronal fuel, bypassing glucose metabolism impairment in AD; reduces neuroinflammation; clinical evidence in epilepsy, AD, and depression
• Intermittent fasting — promotes neuronal autophagy, BDNF upregulation, and mitochondrial biogenesis
• Exercise — the most potent BDNF stimulator available; aerobic exercise reduces neuroinflammation, promotes hippocampal neurogenesis, and improves depression, anxiety, ADHD, and cognitive function
• Sleep optimization — the glymphatic system — the brain's waste clearance system — operates primarily during deep sleep; chronic sleep deprivation accelerates amyloid accumulation and neuroinflammation
• Gut restoration — addressing dysbiosis and leaky gut reduces neuroinflammatory drive via the gut-brain axis (see our Gut Microbiome guide)

Integrative Neurological & Mental Health Protocol

• LDN (1.5–4.5mg/day) — microglial suppression, TLR4 antagonism
• CBD (25–100mg/day) — 5-HT1A, FAAH inhibition, microglial CB2, BDNF upregulation
• Lion's Mane (500–1000mg/day) — NGF synthesis, neurogenesis
• Curcumin (500–1000mg/day enhanced) — BBB-penetrating anti-neuroinflammatory
• Omega-3 (2–3g EPA+DHA/day) — neuronal membrane integrity, anti-neuroinflammatory
• Magnesium L-threonate (2000mg/day) — synaptic density, anxiety, cognitive function
• Ashwagandha (300–600mg/day) — cortisol reduction, HPA axis regulation
• NAD+ precursors (500mg NMN or NR/day) — neuronal mitochondrial support
• Ketogenic or low-carbohydrate diet — neuronal fuel optimization
• Exercise (aerobic + resistance, 4–5x/week) — BDNF, neurogenesis, neuroinflammation reduction
• Gut restoration protocol — probiotics, prebiotics, L-glutamine, gut-brain axis support
• Sleep optimization (7–9 hours) — glymphatic clearance, neuroinflammation resolution

This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before beginning any new health protocol.

Key References

• Cairns, D.M. et al. — LDN as a neuroinflammatory modulator in mental health and neurological conditions.
• Andries, K. et al. — Gut-brain axis dysregulation in depression and neurological disease.
• Noori, S. et al. — Natural anti-neuroinflammatory compounds in mental health conditions.
• Seyyedabadi, B. et al. — IL-6/STAT3 neuroinflammatory signaling in Alzheimer's disease.
• Makis, W. et al. — Ivermectin: neuroprotective and anti-neuroinflammatory potential.
• Seyfried, T.N. et al. — Mitochondrial metabolic dysfunction as a driver of neurodegeneration and mental health disorders.